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Reply from W. F. Maragos 
and col leagues 
SIR: 
We are pleased that our View- 
point article I has provoked a res- 
ponse. Our article was intention- 
ally speculative and intended to 
stimulate experimental work in 
this area. Hardy and Cowburn 
contend that our hypothesis that 
some of the damage in dementia 
of the Alzheimer type (DAT) is 
due to glutamate excitotoxicity is 
not warranted. They argue that 
experimental evidence suggests 
that glutamatergic function (as 
well as that of several other 
neurotransmitters) is underactive 
not overactive in DAT and there- 
fore that glutamate neurotoxicity 
is unlikely. They suggest further 
that the NMDA receptor losses 
seen by Greenamyre et al. 2'3 re- 
f lec t  loss of uptake sites rather 
than receptors. 
Contrary to the statements by 
Hardy and Cowburn, a decrease 
in glutamatergic neurons does 
not imply that excitotoxic mech- 
anisms play no role in the patho- 
genesis of DAT nor does it imply 
that the glutamatergic system is 
'underactive'. It simply suggests 
that as the disease progresses, 
glutamatergic neurons are them- 
selves damaged. Post-mortem 
studies in DAT reflect end-stage 
rather than early disease, i3iopsy 
studies during mid-stage disease 
have shown normal levels of glu- 
tamate release 4. There may be 
relative glutamatergic overactivity 
in early disease. 
We believe there is no reason 
to hypothesize that some of the 
damage in DAT may be related to 
excitotoxicity. Anatomical evi- 
dence suggests that the damage 
in DAT (plaques and tangles) 
propagates along putative gluta- 
matergic pathways such as corti- 
cocortical association path- 
ways s'6, and the pathway con- 
necting the amygdala and nu- 
cleus basalis of Meynert 7. Gluta- 
mate toxicity provides a potential 
explanation for this anatomical 
correlation. 
We do not contend that gluta- 
mate toxicity is the underlying 
cause of Alzheimer's disease, only 
that it may be an agent in the 
destructive process. If neurons 
were rendered unable to maintain 
normal hyperpolarization by any 
process, they would be more sus- 
ceptible to subsequent excitotoxic 
insults because the NMDA sub- 
type of receptor is gated by mag- 
nesium in a voltage-dependent 
fashion 8. Excess activation of 
NMDA receptors is neurotoxic 
and any partially depolarized 
neuron is thus more susceptible to 
neurotoxicity. 
Cotman's laboratory has found 
decreases in NMDA receptors in 
advanced DA'I "9 and has reported 
an average loss of 40% TCP 
binding I°, similar to our own 
findings using a well-defined as- 
say 11. In a large group of early 
and late DAT brains analysed 
blindly, we have recently repeat- 
ed our original experiments and 
found results similar to Cotman's, 
i.e. NMDA receptors were de- 
creased by 40-50% as were TCP 
receptors. Furthermore, receptor 
losses correlated with the num- 
bers of plaques and tangles 
(Maragos, W. F. et aL, unpub- 
lished observations). 
Hardy and Cowburn's concern 
that NMDA-sensitive binding in 
the presence of chloride may, in 
part, represent binding to uptake 
sites is not substantiated experi- 
mentally. We have been unable 
to find any loss of NMDA binding 
after lesions of several gluta- 
matergic pathways, and NMDA 
sites are decreased by >90% after 
lesion of postsynaptic neurons 
(Maragos, W.F., PhD Disserta- 
tion, University of Michigan). Fur- 
thermore, there is evidence that 
NMDA receptor binding actually 
increases in the presence of chlor- 
ide (Ref. 12 and HonorE, T., pers. 
commun.). 
There is substantial evidence 
implicating the glutamatergic sys- 
tem in learning and memory 13-16. 
Therefore, we have hypothesized 
that disruption of the glutamater- 
gic system accounts for some of 
the clinical manifestations in DAT. 
We agree with Hardy and Cow- 
burn that the functional changes 
of DAT likely reflect severe cir- 
cuitry damage. However, rather 
than simply ascribe the signs and 
symptoms of DAT to 'circuitry 
damage', it seems prudent to 
attempt to define which neuro- 
chemical systems are primarily 
responsible for the clinical mani- 
festations of DAT. Only by mak- 
ing hypotheses and testing them 
experimentally will effective, 
rational therapies be developed. 
W. F. Maragos, J. T. Greenamyre, 
J. B. Penney and A. B. Young 
Department of Neurology and Neuroscience 
Program, University of Michigan, Ann Arbor, MI 
48104, USA. 
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ERRATUM 
In the article 'Galanin: a newly isolated biologically 
active neuropeptide' by/~ke R6kaeus (April 1987, Vol. 
10, pp. 158-164), footnote d was misplaced in Table I. 
it should refer to guinea-pig irnnmunohistochernistry in 
the gastrointestinal tract, not mouse. 
We apologize for this error. 
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